Format

Send to

Choose Destination
Curr Opin Investig Drugs. 2002 Sep;3(9):1284-90.

The impact of beta-lactamases on the development of novel antimicrobial agents.

Author information

1
Johnson & Johnson Pharmaceutical Research & Development LLC, 1000 Route 202, Raritan, NJ 08869, USA. kbush@prdus.jnj.com

Abstract

beta-Lactamases have been critical factors for the selection and development of beta-lactam-containing antibacterial agents for almost 60 years. New agents under investigation continue to be evaluated based on their interactions with beta-lactamases. Oral carbapenems, penems and antimethicillin-resistant Staphylococcus aureus cephalosporins are all being selected for development, in part, because of their stability to hydrolysis by the beta-lactamases of their target organisms. beta-Lactamase inhibitors must selectively inhibit the major beta-lactamase groups appearing in current clinical isolates. For all agents, the multiplicity of beta-lactamases in single organisms or in mixed infections poses a new set of challenges requiring agents that can respond to enzymes with varying functional characteristics.

PMID:
12498001
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center